scholarly journals Is It Relevant to Screen Subclinical Cushing’s Syndrome in Patients With Type 2 Diabetes Mellitus?

2017 ◽  
Vol 7 (6) ◽  
pp. 178-184
Author(s):  
Manel Jemel Hadiji ◽  
Imen Ksira ◽  
Emna Haouat ◽  
Henda Kammoun Jamoussi ◽  
Leila Ben Salem Hachmi
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cushing’S Syndrome ◽  
Cushing's Syndrome ◽  
Subclinical Cushing’S Syndrome

scholarly journals Is it worthwhile to screen patients with type 2 diabetes mellitus for subclinical Cushing's syndrome?

2015 ◽  
Vol 4 (4) ◽  
pp. 242-248 ◽  
Author(s):  
Sweta Budyal ◽  
Swati Sachin Jadhav ◽  
Rajeev Kasaliwal ◽  
Hiren Patt ◽  
Shruti Khare ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cushing’S Syndrome ◽  
Serum Cortisol ◽  
Cushing's Syndrome ◽  
Single Center ◽  
Subclinical Cushing’S Syndrome ◽  
Single Center Study ◽  
Center Study

Variable prevalence of subclinical Cushing's syndrome (SCS) has been reported in patients with type 2 diabetes mellitus (T2DM), making the need for screening in this population uncertain. It is unknown if this variability is solely due to study-related methodological differences or a reflection of true differences in ethnic predisposition. The objective of this study is to explore the prevalence of SCS in Asian Indian patients with T2DM. In this prospective single center study conducted in a tertiary care referral center, 993 T2DM outpatients without any discriminatory clinical features (easy bruising, facial plethora, proximal muscle weakness, and/or striae) of hypercortisolism underwent an overnight 1 mg dexamethasone suppression test (ODST). ODST serum cortisol ≥1.8 μg/dl was considered positive, and those with positive results were subjected to 48 h, 2 mg/day low dose DST (LDDST). A stepwise evaluation for endogenous hypercortisolism was planned for patients with LDDST serum cortisol ≥1.8 μg/dl. Patients with positive ODST and negative LDDST were followed up clinically and re-evaluated a year later for the development of clinically evident Cushing's syndrome (CS). In this largest single center study reported to date, we found 37 out of 993 (3.72%) patients had ODST serum cortisol ≥1.8 μg/dl. None of them had LDDST cortisol ≥1.8 μg/dl, nor did they develop clinically evident CS over a follow-up period of 1 year. Specificity of ODST for screening of CS was 96.3% in our cohort. None of the T2DM outpatients in our cohort had SCS, hence cautioning against routine biochemical screening for SCS in this cohort. We suggest screening be based on clinical suspicion only.

Abstract #1214: Decreasing Hypoglycemia Without Compromising Efficacy in an Aging Type 2 Diabetes Mellitus (T2Dm) Population

2015 ◽  
Vol 21 ◽  
pp. 280-281
Author(s):  
Medha Munshi ◽  
Jasvinder Gill ◽  
Jason Chao ◽  
Elena Nikonova ◽  
Andreas Stuhr ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus

Abstract #517: Predicting Risk of Osteoporotic Fracture by Bone Ultrasonography in Type 2 Diabetes Mellitus

2015 ◽  
Vol 21 ◽  
pp. 106
Author(s):  
Franco Grimaldi ◽  
Laura Tonutti ◽  
Claudia Cipri ◽  
Cecilia Motta ◽  
Maria Antonietta Pellegrini ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Osteoporotic Fracture ◽  
Bone Ultrasonography
Sign in / Sign up

Export Citation Format

Share Document